N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07483073

Registry updated: 2026-10-22
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.

Interventions

  • Mirikizumab - Intravenous (IV) (Drug)
    Administered IV
  • Mirikizumab - Subcutaneous (SC) (Drug)
    Administered SC
  • LY4395089 (Drug)
    Administered orally

Eligibility criteria

Inclusion Criteria: * Must have an established diagnosis of Ulcerative Colitis (UC) or Crohn's Disease (CD) for at least 3 month duration, which includes clinical and endoscopic evidence of UC or CD and a histopathology report that supports a diagnosis of UC or CD. * For UC: * Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5-9 points and Endoscopic Subscore (ES) greater than or equal to (≥) 2, confirmed by the central reader and rectal bleeding (RB)≥1. * For CD: * Have moderately to severely active CD as defined by a Crohn's disease activity index (CDAI) score ≥ 220 and less than or equal to (≤) 450. Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6 for participants with ileal-colonic or ≥4 for participants with isolated ileal disease. * Must have demonstrated an inadequate response, loss of response, or intolerance to at least one of the following: corticosteroids, immunomodulators, or an advanced therapy for UC or CD * Have screening laboratory test results within the protocol specified parameters. Exclusion Criteria: * Must not have a current diagnosis of inflammatory bowel disease (IBD)-unclassified or primary sclerosing cholangitis * For UC - must not have a current diagnosis of CD * For CD - must not have a current diagnosis of UC * Must not have had or will need bowel resection or intestinal or intra-abdominal surgery as specified in the protocol * Must not have complications of UC or CD, including but not limited to stricture or stenosis (some exceptions allowed for CD) or short bowel syndrome * Must not have a significant uncontrolled illness that in the opinion of the investigator may compromise the participant's safety or interfere with interpretation of data * Must not have failed more than 5 approved advanced treatments for UC or CD with different mechanisms of action * Must not have failed an anti-interleukin-23p19 (anti-IL-23p19) antibody treatment * Must not have received or will need any prohibited medications for UC or CD as specified in the protocol

Conditions

Colitis, Ulcerative Crohn Disease

Locations

  • Mayo Clinic in Arizona - Scottsdale — Scottsdale, Arizona, United States
  • Biopharma Informatic, LLC — Los Angeles, California, United States
  • Om Research LLC — Oxnard, California, United States
  • South Denver Gastroenterology — Englewood, Colorado, United States
  • Gastro Health Research - Miami — Miami, Florida, United States
  • Ezy Medical Research — Miami Lakes, Florida, United States
  • Atlanta Gastroenterology Associates - Peachtree Dunwoody — Atlanta, Georgia, United States
  • Rush University Medical Center — Chicago, Illinois, United States
  • Cotton O'Neil Digestive Health Center — Topeka, Kansas, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center — Wyoming, Michigan, United States
  • KAD Clinical Research — St Louis, Missouri, United States
  • Vector Clinical Trials — Las Vegas, Nevada, United States
  • One of a Kind Clinical Research Center - Kingwood — Kingwood, Texas, United States
  • Southern Star Research Institute — San Antonio, Texas, United States
  • AZ Maria Middelares — Ghent, Belgium
  • UZ Gent — Ghent, Belgium
  • UZ Leuven — Leuven, Belgium
  • AZ Delta vzw — Roeselare, Belgium
  • Loema Instituto de Pesquisa Clinica — Campinas, Brazil
  • Fundação Universidade de Caxias do Sul (FUCS) — Caxias do Sul, Brazil
  • Centro Digestivo de Curitiba — Curitiba, Brazil
  • Centro de Pesquisa Clínica de Marília - CPCLIM — Marília, Brazil
  • CPHosp Medicina, Ensino e Pesquisa (CPQuali) — São Paulo, Brazil
  • CPCLIN — São Paulo, Brazil
  • BR Trials - Ensaios Clinicos e Consultoria — São Paulo, Brazil
  • Clínica Hepatogastro JK — São Paulo, Brazil
  • CEDOES — Vitória, Brazil
  • Prairie Institute of Liver and Luminal Advanced Research Ltd (PILLAR) — Lethbridge, Canada
  • London Digestive Disease Institute — London, Canada
  • Tdda Inc. — Vaughan, Canada
  • The Second Xiangya Hospital of Central South University — Changsha, China
  • Changzhou Second People's Hospital — Changzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University — Guangzhou, China
  • The Second Affiliated hospital of Zhejiang University school of medicine — Hangzhou, China
  • Huizhou Central People's Hospital — Huizhou, China
  • The Second Affiliated Hospital of Soochow University — Suzhou, China
  • The Second Affiliated Hospital YuYing Childens Hospital of Wenzhou Medical university — Wenzhou, China
  • Zhongshan Hospital Affiliated to Xiamen University — Xiamen, China
  • Affiliated Hospital of Jiangsu University — Zhenjiang, China
  • Charité Universitaetsmedizin Berlin - Campus Mitte — Berlin, Germany
  • Studienzentrum MVZ Dachau — Dachau, Germany
  • Studiengesellschaft Mitteldeutschland GmbH — Halle, Germany
  • St. Marien- und St. Annastiftskrankenhaus — Ludwigshafen, Germany
  • Universitaetsklinikum Ulm — Ulm, Germany
  • Geomedical Egészségügyi Központ — Budapest, Hungary
  • Semmelweis Egyetem — Budapest, Hungary
  • Komarom-Esztergom Varmegyei Szent Borbala Korhaz — Tatabánya, Hungary
  • Assuta Ashdod Medical Center — Ashdod, Israel
  • Rambam Health Care Campus — Haifa, Israel
  • Shaare Zedek Medical Center — Jerusalem, Israel
  • Hadassah Medical Center — Jerusalem, Israel
  • Rabin Medical Center — Petah Tikva, Israel
  • Sheba Medical Center — Ramat Gan, Israel
  • Yitzhak Shamir Medical Center — Ẕerifin, Israel
  • Azienda Ospedaliera Universitaria Careggi — Florence, Italy
  • Ospedale San Raffaele — Milan, Italy
  • Fondazione IRCCS San Gerardo dei Tintori — Monza, Italy
  • Ospedale Sacro Cuore Don G. Calabria — Negrar, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli — Roma, Italy
  • Humanitas — Rozzano, Italy
  • Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero — Katowice, Poland
  • Centrum Medyczne Oslomed — Krakow, Poland
  • Medrise Sp. z o.o. — Lublin, Poland
  • Twoja Przychodnia PCM — Poznan, Poland
  • ETG Siedlce — Siedlce, Poland
  • Twoja Przychodnia SCM — Szczecin, Poland
  • Sonomed Sp. z o. o. — Szczecin, Poland
  • WSD MEDI — Warsaw, Poland
  • Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś — Warsaw, Poland
  • ETG Zamość — Zamość, Poland
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record